Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.39 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31720760 | 0.90 | KMT2A (0.61) | KMT2ATLR2CASP3 | |
| SCHEMBL28629484 | 0.87 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL28629485 | 0.87 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL31758332 | 0.87 | KMT2A (0.58) | KMT2ATLR2TLR1MDM2MAPT | |
| Hydrochloric Acid SCHEMBL29380070 | 0.86 | KMT2A (0.57) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL732427 | 0.84 | KMT2A (0.68) | KMT2ATLR2TLR1MALT1MDM2 | |
| SCHEMBL29823506 | 0.83 | KMT2A (0.52) | KMT2ATLR2CASP3 | |
| SCHEMBL4906458 | 0.83 | KMT2A (0.54) | KMT2ATLR2TLR1MDM2MAPT | |
| SCHEMBL17246795 | 0.82 | MDM2 (0.53) | KMT2ATLR2TLR1MDM2 | |
| SCHEMBL23446680 | 0.82 | KMT2A (0.54) | KMT2ATLR2TLR1MDM2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| EP-4583845-A1 | PROGRAMMABLE STIMULI-RESPONSIVE POLYMERIC FORMULATIONS | Ramot at Tel-Aviv University Ltd. (IL) | 2025-07-16 | — | — | EP | disclosed |
| US-20250122260-A1 | GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES | ZEALAND PHARMA A/S (DK) | 2025-04-17 | — | — | US | disclosed |
| WO-2024052920-A1 | PROGRAMMABLE STIMULI-RESPONSIVE POLYMERIC FORMULATIONS | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-03-14 | — | — | WO | disclosed |
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | HANMI FINE CHEMICAL CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | VIP, IAPP, ANPEP | KMT2A 4831/4885TLR2 4439/4885TLR1 4339/4885 |
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | VIP, PTMS, HM13 | KMT2A 3953/4885TLR2 4053/4885TLR1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.